In line with some previous reports (6, 21) we confirmed that in our cohort of early RA patients the anti-CCP3.1 assay showed indeed a slightly higher sensitivity than the anti-CCP2 IgG assay. The gene discussed is AGBL2; the disease is rheumatoid arthritis.